Thinly traded micro cap Corvus Pharmaceuticals (CRVS +3.6%) perks up on below-average volume on the heels of updated data from a Phase 1/1b clinical trial evaluating CPI-818 in patients with T-cell lymphomas. The results were presented at the T-Cell Lymphoma Forum in La Jolla, CA.
No dose-limiting toxicities or
serious/life-threatening treatment-related adverse events have been
observed in 16 subjects who have received one of four strengths (100 mg –
600 mg) of CPI-818 twice daily.
Median follow-up is now three months. 11 patients
remain on therapy. One patient with cutaneous T-cell lymphoma (CTCL) who
received the 200 mg dose showed a reduction in lymphadenopathy and
improved PET scan while another CTCL patient who received 400 mg showed
improved cutaneous disease.
Pharmacokinetics and occupancy studies have been consistent with expectations.
Orally administered CPI-818 is a small molecule
T-cell signaling pathway inhibitor. Specifically, it inhibits an enzyme
called interleukin-2-inducible T-cell kinase (ITK) and is designed to
block malignant T cell growth and modulate immune responses.
https://seekingalpha.com/news/3537354-corvus-pharma-up-4-on-updated-cpiminus-818-data
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.